smartShift Revolutionizes SAP Modernization with AI-Powered Revert to Standard
Poised to Redefine SAP ERP Modernization, smartShift Unveils AI-Powered Platform to Accelerate Revert to Standard.
Boston, MA, May 14, 2025 (GLOBE NEWSWIRE) -- smartShift, a global leader in SAP custom code transformation, today announced the development of a groundbreaking AI-powered solution designed to help SAP customers accelerate their transition to a Clean Core. This innovation empowers organizations to systematically identify and replace custom ABAP code with standard SAP functionality, streamlining operations and preparing for SAP S/4HANA and RISE with SAP.
As enterprises seek to simplify their ERP environments, reverting to standard SAP processes has become a strategic imperative. Yet, identifying viable standard alternatives for custom-built functionality remains a manual, complex, and time-intensive challenge, often slowing progress or stalling initiatives altogether.
smartShift is harnessing the power of Large Language Model (LLM) agentic AI to automate the analysis of legacy custom code, intelligently mapping it to the latest standard SAP features. This approach enables SAP customers to objectively assess whether custom logic is still necessary or can be safely retired in favor of modern, native capabilities.
'Simplification is the new innovation,' said Jagdish Sahasrabudhe, CTO of smartShift. 'Our customers are demanding smarter, faster ways to eliminate unnecessary custom code and embrace the SAP standard. With SAP delivering continuous innovation, the time is now to revisit outdated customizations and let AI lead the way back to standard.'
By enabling organizations to reduce technical debt, lower total cost of ownership, and accelerate digital transformation, smartShift is setting a new benchmark for SAP modernization.
'smartShift has been solving the SAP custom code challenge long before it became a popular talking point,' said Derek Oats, CEO of smartShift. 'Our platform has delivered thousands of real-world solutions over more than a decade, long before Clean Core was a mainstream concept. While others are now entering the conversation with slick messaging and an older, archaic operating model, we're bringing substance, scale, and proven impact. This isn't a trend for us—it's our foundation.'
With AI at the core of its innovation strategy, smartShift continues to lead the charge in enabling SAP customers to simplify, standardize, and future-proof their ERP landscapes—turning Clean Core ambition into operational reality.
Learn more about smartShift, supercharged with AI: https://smartshift.com/future
smartShift is a global leader in SAP custom code transformation for SAP S/4HANA and Clean Core. We empower businesses to modernize their SAP landscapes, eliminate technical debt, and embrace future-ready development. Our automated and patented AI-powered solutions deliver secure, stable, and optimized code addressing all custom code issues, not just those prioritized for manual remediation with a fixed-price, fixed-timeline, and 100% quality guarantee. Trusted by SAP's largest customers, smartShift has a proven track record of modernizing over 3,300 SAP systems and converting more than 3.5 billion lines of code.
CONTACT: Michelle Bissonnette smartShift 617-528-2100 mbissonnette@smartshift.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China
Builds on clearances already received by FDA and EMA China has the largest population of patients with hepatocellular carcinoma in the world BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that the company received approval from the National Medical Products Administration (NMPA) in China to proceed with a pivotal trial to evaluate amezalpat (TPST-1120) in combination with atezolizumab and bevacizumab, the current standard of care, versus the standard of care alone in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC). 'This regulatory clearance to proceed with a pivotal trial in China is a significant milestone towards reaching global markets where HCC has high prevalence,' said Sam Whiting M.D., Ph.D., chief medical officer and head of R&D of Tempest. 'It is rewarding that the regulatory officials in China see the promise and potential of amezalpat and have provided the green light to begin a registration-directed trial. We strongly believe amezalpat is a drug that can make a difference in the lives of patients with HCC and believe it should be advanced to pivotal testing.' About the TPST-1120-301 Study (NCT06680258) The planned Phase 3 study is a global, blinded, 1:1 randomized study of amezalpat plus atezolizumab and bevacizumab versus placebo plus atezolizumab and bevacizumab, the standard of care, for the first-line treatment of patients with unresectable or metastatic HCC. The company has also received agreement from the FDA and EMA on its Phase 3 study design, dose of amezalpat, and the statistical plan, including a pre-specified efficacy analysis that could shorten the time to primary analysis. About Hepatocellular Carcinoma HCC is an aggressive cancer with rising mortality and is projected to become the third leading cause of cancer death by 2030.1 Every year, more than 900,000 people worldwide are diagnosed with HCC.2 Incidence and mortality are highest in East Asia and are increasing in parts of Europe and the US.3 In the US, HCC represents the fastest-rising cause of cancer-related death.3 Nine out of ten cases of HCC are caused by chronic liver disease, which includes chronic hepatitis B and C infection, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcohol-related liver disease (ALD) and cirrhosis resulting from these conditions.4 Even if diagnosed in the early stage, an estimated 70-80% of people with early-stage HCC experience disease recurrence following surgery.5 Early recurrence is associated with poorer prognosis and shorter survival.5,6 Tumor size, number of tumors, and portal vein invasion are associated with an increased risk of recurrence.6 About Amezalpat Amezalpat is an oral, small molecule, selective PPAR⍺ antagonist. Data suggest that amezalpat treats cancer by targeting tumor cells directly and by modulating immune suppressive cells and angiogenesis in the tumor microenvironment. In an ongoing global randomized Phase 1b/2 study of amezalpat in combination with atezolizumab and bevacizumab in first-line patients with advanced HCC, the amezalpat arm showed clinical superiority across multiple study endpoints, including overall survival in both the entire population and key subpopulations, when compared to atezolizumab and bevacizumab alone, the standard of care. These randomized data were supported by additional positive results observed in the Phase 1 clinical trial in patients with heavily pretreated advanced solid tumors, including renal cell carcinoma and cholangiocarcinoma. About Tempest Therapeutics Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company's novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company's website at Forward-Looking Statements This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (the 'Securities Act')) concerning Tempest Therapeutics, Inc. These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Tempest Therapeutics, as well as assumptions made by, and information currently available to, management of Tempest Therapeutics. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'may,' 'will,' 'should,' 'would,' 'could', 'expect,' 'anticipate,' 'plan,' 'likely,' 'believe,' 'estimate,' 'project,' 'intend,' and other similar expressions. All statements that are not historical facts are forward-looking statements, including any statements regarding: the design, initiation, progress, timing, scope and results of clinical trials, including the anticipated Phase 3 study for amezalpat; anticipated therapeutic benefit and regulatory development of the Company's product candidates the Company's ability to advance into a late-stage clinical company; and the Company's ability to achieve its operational plans. Forward-looking statements are based on information available to Tempest Therapeutics as of the date hereof and are not guarantees of future performance. Any factors may cause differences between current expectations and actual results, including: unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes in expected or existing competition; changes in the regulatory environment; and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied are discussed in greater detail in the 'Risk Factors' section of the Company's Quarterly Report on Form 10-Q filed for the quarter ended March 31, 2025 and other documents filed by the Company from time to time with the Securities and Exchange Commission. Except as required by applicable law, Tempest Therapeutics undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Tempest Therapeutics' views as of any date subsequent to the date of this press release and should not be relied upon as prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Tempest Therapeutics. Investor Contacts: Sylvia WheelerWheelhouse Life Science Advisorsswheeler@ Aljanae Reynolds Wheelhouse Life Science Advisorsareynolds@ i If approved by the FDA 1 Rahib, L. et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74, 2913-2921 (2014).2 World Health Organization. Liver Cancer Factsheet. Globocan. 2020. Available at: Last accessed: April 2023.3 Llovet, J. M., Kelley, R. K., Villanueva, A., et al. Hepatocellular carcinoma. Nature Reviews Disease Primers. 2021, 7(1), 6.4 Office for Health Improvement & Disparities. Liver disease profiles: November 2021 update. Available at: Last accessed: April 2023.5 Hack SP, Spahn J, Chen M et al. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncology. 2020 May;16(15):975-989.6 Saito A, Toyoda H, Kobayashi M et al. Prediction of early recurrence of hepatocellular carcinoma after resection using digital pathology images assessed by machine learning. Modern Pathology. 2021. 34, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
2 hours ago
- Business Upturn
insightsoftware Brings JustPerform to France, Supporting Finance Teams with AI Powered Financial Companion
RALEIGH, N.C. and PARIS, June 30, 2025 (GLOBE NEWSWIRE) — insightsoftware , the most comprehensive provider of solutions for the Office of the CFO, today announced that JustPerform is now available in France. This intelligent financial planning, forecasting, and close companion empowers French finance teams to work smarter, not harder. It seamlessly blends human expertise with AI capabilities that feel like having the most insightful colleague always at your side. French finance professionals know the frustration: endless hours wrestling with spreadsheets, chasing down data from multiple systems, and scrambling to meet closing deadlines while trying to deliver strategic insights that actually drive business value. JustPerform transforms this daily reality by working alongside teams as an intelligent companion that understands how finance teams think and work. Lineos, AI powered by insightsoftware, is woven throughout the JustPerform experience, giving teams a trusted partner that streamlines every process. Lineos delivers critical insights through predictive forecasting that anticipates what's ahead and anomaly detection that catches what others miss. Lineos is intelligence built into the fabric of how modern finance teams work. It enables collaboration for you to close faster, report with confidence, and make decisions that matter. 'Finance teams shouldn't spend their expertise fighting technology – they should spend it solving business challenges,' said Elisabeth Rambert, Regional Vice President of France at insightsoftware. 'JustPerform represents our commitment to giving French finance professionals the modern tools they deserve to focus on what matters most. Further, it reinforces our commitment to the French market, which we've been honored to serve for more than 20 years with other comprehensive solutions for the Office of the CFO.' The solution puts business users in control, enabling them to master any process in under five minutes. French organizations using JustPerform are seeing 40% faster budget preparation, 60% time savings in data transformation, and 2x return on investment delivered in half the typical timeframe. In the coming months, JustPerform will also be able to set up multiple customer instances, enabling CPA firms to take advantage of the solution's capabilities. In addition to France, JustPerform is available in North America, the UK, Ireland, and APAC. Discover how JustPerform helps finance teams achieve 40% faster budget preparation, 2x quicker ROI, and 60% time savings in data transformation. Join the 'How to transform your financial planning in 2025' webinar on July 2, 2025 at 17:30. Register here. About insightsoftware insightsoftware is a global provider of comprehensive solutions for the Office of the CFO. We believe an actionable business strategy begins and ends with accessible financial data. With solutions across financial planning and analysis (FP&A), accounting, and operations, we transform how teams operate, empowering leaders to make timely and informed decisions. With data at the heart of everything we do, insightsoftware enables automated processes, delivers trusted insights, boosts predictability, and increases productivity. Learn more at Media ContactsInkhouse for insightsoftware [email protected]
Business Upturn
2 hours ago
- Business Upturn
Air Cairo Sets New Benchmark for African Airlines: Enhances In-Flight Medical Safety with MedAire Partnership
Cairo, Egypt, June 30, 2025 (GLOBE NEWSWIRE) — Air Cairo, one of Egypt's leading airlines, has partnered strategically with MedAire, the global leader in aviation medical and security support, to enhance its in-flight medical capabilities and operational efficiencies. This partnership aligns with the Egyptian Ministry of Civil Aviation's vision to modernise and elevate safety and healthcare standards across the air transport sector. The agreement was formally signed by Captain Ahmed Shanan, Chairman and CEO of Air Cairo, and Reely Rajan, Director of Middle East, Africa, India, and Asia at MedAire, in the presence of Captain Amr El-Sharkawy, Chairman of the Egyptian Civil Aviation Authority. This collaboration underscores Air Cairo's commitment to adopting global best practices in aviation health and safety, ensuring the highest standards of passenger care. Under this strategic partnership, Air Cairo will implement MedAire's industry-leading MedLink service, providing flight crews with 24/7 real-time access to emergency physicians specialised in aviation medicine. Air Cairo crews will also benefit from offline access to MedAire's industry-first In-Flight App, designed to support medical decision-making without connectivity. These advanced medical services will be deployed fleet-wide across Air Cairo's Airbus A320-200, A320neo, E190 and ATR 72-600 aircraft, supporting key regional routes into the Middle East, Europe, and Africa. Captain Ahmed Shanan, Chairman and CEO of Air Cairo, commented: 'This partnership is a cornerstone of Air Cairo's integrated strategy to enhance aviation safety, reduce operational disruptions, and ensure our crews are fully prepared to manage medical events onboard. Our passengers' safety and comfort remain our highest priority, and MedAire's proven expertise will help us deliver on this commitment.' Air Cairo selected MedAire specifically for its extensive experience in managing complex in-flight medical scenarios and its robust Passenger Fit-to-Fly assessment capabilities. By leveraging MedAire's global infrastructure and medical expertise, Air Cairo aims to proactively manage pre-flight medical cases, reduce unnecessary delays, and ensure compliance with evolving international safety standards. Reely Rajan, Director of Middle East, Africa, India, and Asia at MedAire, stated: 'We are proud to partner with Air Cairo. As our first airline client in Africa, this collaboration sets a new benchmark for in-flight medical safety in the region. It demonstrates Air Cairo's forward-thinking approach to passenger care. Beyond supporting their current operations, our global infrastructure ensures Air Cairo is well-equipped to expand seamlessly into new markets in the future.' The new medical services will go live on all Air Cairo flights starting mid-July 2025. MedAire's comprehensive suite of solutions minimises diversion risks, enhances crew confidence during medical incidents, and strengthens pre-flight medical screening capabilities, ultimately improving operational efficiency and passenger experience. About Air Cairo Air Cairo is Egypt's premier regional airline and a vital part of the country's aviation sector. Established in 2003, the airline has grown into a key player in connecting Egypt to regional and international destinations across the Middle East, Africa, and Europe. Operating a modern fleet of Airbus A320 aircraft, the airline serves both scheduled and charter flights, playing a significant role in supporting Egypt's tourism industry and economic development. Air Cairo remains dedicated to its mission of providing seamless connectivity while contributing to Egypt's vision of becoming a regional aviation hub. About MedAire MedAire, an International SOS company, has been the preferred partner to the aviation industry since 1985. Today, MedAire is the aviation industry's proven leader for integrated travel health and aviation security solutions. Six of the world's largest business jet manufacturers (Boeing, Bombardier, Embraer, Gulfstream, Honda Jet and Textron Aviation) come standard with MedAire's service. Additionally, 180+ of the world's leading airlines and more than 6,800 private aircraft – including 75% of Fortune 100 Companies – trust MedAire for their travel health and security risk management needs. MedAire's integrated solutions include aviation security intelligence, real-time health and security advice and assistance, training, equipment, and professional services for crew and passengers in and beyond the cabin. MedAire handles thousands of calls annually to help crew and passengers manage medical and travel safety events in the air and on the ground with 24/7 access to emergency care doctors, nurses, and aviation security specialists. Attachments Executives Signing Partnership Agreement Signing Ceremony Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
